Microbot Medical’s (MBOT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Microbot Medical (NASDAQ:MBOT) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $12.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Microbot Medical’s Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.32) EPS.

MBOT has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, April 10th. B. Riley Financial started coverage on Microbot Medical in a research note on Tuesday, February 10th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Microbot Medical currently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Microbot Medical Price Performance

Microbot Medical stock opened at $2.39 on Tuesday. The company’s 50-day moving average is $2.39 and its 200-day moving average is $2.32. The firm has a market capitalization of $160.51 million, a PE ratio of -8.24 and a beta of 1.19. Microbot Medical has a fifty-two week low of $1.60 and a fifty-two week high of $4.67.

Microbot Medical (NASDAQ:MBOT) last issued its earnings results on Sunday, March 22nd. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. As a group, analysts expect that Microbot Medical will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Microbot Medical

Several hedge funds have recently bought and sold shares of MBOT. Beacon Capital Management LLC increased its stake in shares of Microbot Medical by 37.5% during the third quarter. Beacon Capital Management LLC now owns 22,000 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 6,000 shares during the period. Cetera Investment Advisers boosted its stake in Microbot Medical by 38.8% in the 4th quarter. Cetera Investment Advisers now owns 29,313 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 8,201 shares during the period. Cornerstone Advisory LLC bought a new stake in Microbot Medical in the 3rd quarter valued at $30,000. Zacks Investment Management acquired a new position in Microbot Medical in the 3rd quarter valued at $33,000. Finally, Squarepoint Ops LLC bought a new position in Microbot Medical during the 3rd quarter worth $37,000. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.